Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 20861593)

1.
2.

Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.

McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, Matthews AG, Sharma G, Van Veldhuisen P, Vandrey RG, Levin FR, Weiss RD, Lindblad R, Allen C, Mooney LJ, Haynes L, Brigham GS, Sparenborg S, Hasson AL, Gray KM.

Contemp Clin Trials. 2014 Nov;39(2):211-23. doi: 10.1016/j.cct.2014.08.011. Epub 2014 Aug 30.

PMID:
25179587
3.

Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder.

Najib J.

Adolesc Health Med Ther. 2012 May 8;3:51-66. doi: 10.2147/AHMT.S19815. eCollection 2012. Review.

4.
5.

Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.

Roesch B, Corcoran ME, Fetterolf J, Haffey M, Martin P, Preston P, Purkayastha J, Wang P, Ermer J.

Drugs R D. 2013 Jun;13(2):119-28. doi: 10.1007/s40268-013-0014-8.

6.

Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse.

Sweeney CT, Sembower MA, Ertischek MD, Shiffman S, Schnoll SH.

J Addict Dis. 2013;32(1):1-10. doi: 10.1080/10550887.2012.759858.

7.

Substance-use disorders in adolescents and adults with ADHD: focus on treatment.

Wilens TE, Morrison NR.

Neuropsychiatry (London). 2012 Aug;2(4):301-312.

8.

Attention-deficit/hyperactivity disorder in older adults: prevalence and possible connections to mild cognitive impairment.

Ivanchak N, Fletcher K, Jicha GA.

Curr Psychiatry Rep. 2012 Oct;14(5):552-60. doi: 10.1007/s11920-012-0305-8. Review.

9.

Stimulant medication use in children: a 12-year perspective.

Zuvekas SH, Vitiello B.

Am J Psychiatry. 2012 Feb;169(2):160-6.

10.

Prenatal Cocaine Disrupts Serotonin Signaling-Dependent Behaviors: Implications for Sex Differences, Early Stress and Prenatal SSRI Exposure.

Williams SK, Lauder JM, Johns JM.

Curr Neuropharmacol. 2011 Sep;9(3):478-511. doi: 10.2174/157015911796557957.

11.

Altered serotonergic function may partially account for behavioral endophenotypes in steroid sulfatase-deficient mice.

Trent S, Cassano T, Bedse G, Ojarikre OA, Humby T, Davies W.

Neuropsychopharmacology. 2012 Apr;37(5):1267-74. doi: 10.1038/npp.2011.314. Epub 2011 Dec 21.

12.

An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Wilens TE, Morrison NR, Prince J.

Expert Rev Neurother. 2011 Oct;11(10):1443-65. doi: 10.1586/ern.11.137. Review.

13.

Attention-deficit/hyperactivity disorder in childhood is associated with cognitive test profiles in the geriatric population but not with mild cognitive impairment or Alzheimer's disease.

Ivanchak N, Abner EL, Carr SA, Freeman SJ, Seybert A, Ranseen J, Jicha GA.

J Aging Res. 2011;2011:729801. doi: 10.4061/2011/729801. Epub 2011 Jul 21.

14.

The intersection of attention-deficit/hyperactivity disorder and substance abuse.

Wilens TE, Morrison NR.

Curr Opin Psychiatry. 2011 Jul;24(4):280-5. doi: 10.1097/YCO.0b013e328345c956. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk